Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.72 |
| ▸ | CHAT | P28329 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL29447134 | 1.00 | SNCA (0.72) | SNCACHATCDK2TTRFABP4 | |
| Potassium Ion SCHEMBL1082232 | 1.00 | SNCA (0.72) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL30261938 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL64271 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL29382721 | 0.84 | SNCA (1.00) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL20574382 | 0.83 | SNCA (0.97) | SNCACHATCDK2TTRFABP4 | |
| Potassium SCHEMBL1082234 | 0.83 | SNCA (0.97) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL2862964 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL591337 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 | |
| SCHEMBL29353590 | 0.79 | THRB (0.53) | SNCACHATCDK2TTRFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | claimed |
| CN-119964633-A | Method for designing and screening compound combined with target protein target by utilizing HomoArt | 上海交通大学医学院附属瑞金医院 | 2025-05-09 | — | — | CN | claimed |
| CN-112639470-B | Diagnostic method for amyloid-related disease | 阿米罗伊迪亚瑞典股份公司 | 2025-02-25 | — | — | CN | claimed |
| US-12174161-B2 | Methods of measuring hydrophobicity of chromatographic resins | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | claimed |
| EP-3254113-B1 | LUCIFERASE-BASED THERMAL SHIFT ASSAYS | PROMEGA CORP (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4427033-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA Biotech GmbH (DE) | 2024-09-11 | — | — | EP | claimed |
| EP-3948262-B1 | METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS | BRISTOL MYERS SQUIBB CO (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3775884-B1 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | AMYLOIDIA SWEDEN AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-113646630-B | Method for measuring hydrophobicity of chromatographic resin | 百时美施贵宝公司 | 2024-05-07 | — | — | CN | claimed |
| WO-2023079052-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| US-20220042954-A1 | METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS | BRISTOL-MYERS SQUIBB COMPANY | 2022-02-10 | — | — | US | claimed |
| EP-3948262-A1 | METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS | Bristol-Myers Squibb Company (US) | 2022-02-09 | — | — | EP | claimed |
| US-20220026446-A1 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | AMYLOIDIA SWEDEN AB (SE) | 2022-01-27 | — | — | US | claimed |
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-20220026437-A1 | PROTEIN MELT ANALYSIS USING DIPYRROMETHENEBORON DIFLUORIDE COMPOUNDS | Life Technologies Corporation | 2022-01-27 | — | — | US | disclosed |
| US-20220026446-A1 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | AMYLOIDIA SWEDEN AB (SE) | 2022-01-27 | — | — | US | disclosed |
| WO-2022020150-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINE1 | SNCA 866/4885CHAT 1637/4885CDK2 4776/4885 |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | SERPINA2, SERPINB1, SERPINE1 | SNCA 866/4885CHAT 2614/4885CDK2 4297/4885 |
| US-20220026437-A1 | PROTEIN MELT ANALYSIS USING DIPYRROMETHENEBORON DIFLUORIDE COMPOUNDS | PFDN6, S100A6, MB | SNCA 2251/4885CHAT 4861/4885CDK2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.